A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

被引：3

作者：

Pemmaraju, Naveen

Marconi, Giovanni

Todisco, Elisabetta

Montesinos, Pau

Lane, Andrew A.

Sweet, Kendra

Wang, Eunice S.

Deconinck, Eric

Rizzieri, David A.

Walter, Roland B.

Aribi, Ahmed

Lebon, Delphine

Levy, Moshe Y.

Mazzarella, Luca

Martinelli, Giovanni

Gigli, Federica

Erba, Harry P.

Acuna-Cruz, Evelyn

Konopleva, Marina

Kantarjian, Hagop

Sloss, Callum M.

Wang, Jiuzhou

Malcolm, Kara E.

Zweidler-McKay, Patrick A.

DeAngelo, Daniel J.

Daver, Naval

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Ist Seragnoli, Bologna, Italy

[3] European Inst Oncol IRCCS, Div Onco Hematol, Milan, Italy

[4] Hosp Univ & Politecn La Fe, Valencia, Spain

[5] Dana Farber Boston Childrens Canc & Blood Disorde, Dept Med Oncol, Boston, MA USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[7] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[8] Besancon Univ Hosp, Clin Hematol, Besancon, France

[9] Duke Univ Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Med, Durham, NC USA

[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[11] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA USA

[12] CHU Amiens, Hematol Dept, Amiens, France

[13] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[14] European Inst Oncol, Milan, Italy

[15] Inst Hematol LeA Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[16] European Inst Oncol, Milan, Italy

[17] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] ImmunoGen, Waltham, MA USA

[20] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146681

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4429

引用

页数：10

共 50 条

[41] Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
Manisha H. Shah
Paul Lorigan
Mary E. R. O’Brien
Frank V. Fossella
Kathleen N. Moore
Shailender Bhatia
Maurice Kirby
Penella J. Woll
Investigational New Drugs, 2016, 34 : 290 - 299
[42] Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma
Younes, A.
Forero-Torres, A.
Bartlett, N. L.
Leonard, J. P.
Rege, B.
Kennedy, D. A.
Lorenz, J. M.
Sievers, E. L.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[43] Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma
Younes, A.
Forero-Torres, A.
Bartlett, N. L.
Leonard, J. P.
Rege, B.
Kennedy, D. A.
Lorenz, J. M.
Sievers, E. L.
ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
[44] Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
Anastasios Stathis
Ian W. Flinn
Sumit Madan
Kami Maddocks
Arnold Freedman
Steven Weitman
Emanuele Zucca
Mihaela C. Munteanu
M. Lia Palomba
Investigational New Drugs, 2018, 36 : 869 - 876
[45] Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
Stathis, Anastasios
Flinn, Ian W.
Madan, Sumit
Maddocks, Kami
Freedman, Arnold
Weitman, Steven
Zucca, Emanuele
Munteanu, Mihaela C.
Palomba, M. Lia
INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 869 - 876
[46] BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Jagannath, Sundar
Chanan-Khan, Asher A.
Heffner, Leonard T.
Avigan, David
Lutz, Robert J.
Uherek, Christoph
Osterroth, Frank
Ruehle, Markus
Haeder, Thomas
Niemann, Gabriele
Wartenberg-Demand, Andrea
Munshi, Nikhil C.
Anderson, Kenneth C.
BLOOD, 2010, 116 (21) : 1262 - 1262
[47] Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Herrera, Alex F.
Carlo-Stella, Carmelo
Collins, Graham P.
Maddocks, Kami J.
Bartlett, Nancy L.
Savage, Kerry J.
Caimi, Paolo F.
Hess, Brian T.
Zinzani, Pier Luigi
Cruz, Hans G.
Wang, Luqiang
Feingold, Jay
Wuerthner, Jens
Ansell, Stephen M.
BLOOD, 2020, 136
[48] Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma
Herrera, Alex F.
Carlo-Stella, Carmelo
Collins, Graham P.
Maddocks, Kami J.
Bartlett, Nancy L.
Savage, Kerry J.
Caimi, Paolo F.
Hess, Brian T.
Zinzani, Pier Luigi
Cruz, Hans G.
Wang, Luqiang
Feingold, Jay
Wuerthner, Jens
Ansell, Stephen M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 13 - 14
[49] Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Advani, Ranjana H.
Lebovic, Daniel
Chen, Andy
Brunvand, Mark
Goy, Andre
Chang, Julie E.
Hochberg, Ephraim
Yalamanchili, Sreeni
Kahn, Robert
Lu, Dan
Agarwal, Priya
Dere, Randall C.
Hsieh, Hsin-Ju
Jones, Surai
Chu, Yu-Waye
Cheson, Bruce D.
CLINICAL CANCER RESEARCH, 2017, 23 (05) : 1167 - 1176
[50] Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
Stathis, Anastasios
Maddocks, Kami J.
Flinn, Ian
Mejia, Alex
Palomba, Maria Lia
Zildjian, Sybil
Murphy, Mary
Deckert, Jutta
Ruiz-Soto, Rodrigo
Freedman, Arnold
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →